ObsEva Stock Forecast, Price & News

ObsEva (NASDAQ:OBSV) Frequently Asked Questions

Is ObsEva a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ObsEva in the last year. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ObsEva stock.
View analyst ratings for ObsEva or view top-rated stocks.

What stocks does MarketBeat like better than ObsEva?

Wall Street analysts have given ObsEva a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ObsEva wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ObsEva?

ObsEva saw a drop in short interest during the month of August. As of August 13th, there was short interest totaling 1,490,000 shares, a drop of 35.8% from the July 29th total of 2,320,000 shares. Based on an average daily volume of 1,770,000 shares, the days-to-cover ratio is currently 0.8 days. Approximately 2.5% of the shares of the stock are short sold.
View ObsEva's Short Interest.

When is ObsEva's next earnings date?

ObsEva is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for ObsEva.

How were ObsEva's earnings last quarter?

ObsEva SA (NASDAQ:OBSV) released its earnings results on Thursday, August, 5th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.01.
View ObsEva's earnings history.

How has ObsEva's stock been impacted by COVID-19?

ObsEva's stock was trading at $2.57 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, OBSV stock has increased by 22.6% and is now trading at $3.15.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for OBSV?

4 brokerages have issued 12 month price targets for ObsEva's stock. Their forecasts range from $5.00 to $21.00. On average, they expect ObsEva's share price to reach $14.33 in the next twelve months. This suggests a possible upside of 355.0% from the stock's current price.
View analysts' price targets for ObsEva or view top-rated stocks among Wall Street analysts.

Who are ObsEva's key executives?

ObsEva's management team includes the following people:

• Brian O'Callaghan, Chief Executive Officer & Director
• David Renas, Chief Financial Officer
• Jean-Pierre Gotteland, Chief Scientific Officer, Head-R&D
• Elizabeth Ijeoma Onyemelukwe Garner, Chief Medical Officer
• Elke Bestel, VP, Head-Drug Safety & Pharmacovigilance

Who are some of ObsEva's key competitors?

Some companies that are related to ObsEva include Veru (VERU), Lexicon Pharmaceuticals (LXRX), Immuneering (IMRX), Eagle Pharmaceuticals (EGRX), Mersana Therapeutics (MRSN), Emisphere Technologies (EMIS), PyroGenesis Canada (PYR), Imago BioSciences (IMGO), Rhythm Pharmaceuticals (RYTM), Silence Therapeutics (SLN), Pharming Group (PHAR), G1 Therapeutics (GTHX), Rigel Pharmaceuticals (RIGL), Seres Therapeutics (MCRB) and Pliant Therapeutics (PLRX).
View all of OBSV's competitors.

What other stocks do shareholders of ObsEva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ObsEva investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Trevena (TRVN), Zosano Pharma (ZSAN), Vaxart (VXRT), VBI Vaccines (VBIV), Bionano Genomics (BNGO) and ADMA Biologics (ADMA).

When did ObsEva IPO?

(OBSV) raised $98 million in an IPO on Thursday, January 26th 2017. The company issued 6,500,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

What is ObsEva's stock symbol?

ObsEva trades on the NASDAQ under the ticker symbol "OBSV."

Who are ObsEva's major shareholders?

ObsEva's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Morgan Stanley (1.50%), Morgan Stanley (1.50%), Credit Suisse AG (1.47%), Zurcher Kantonalbank Zurich Cantonalbank (0.95%), Susquehanna International Group LLP (0.00%) and Deutsche Bank AG (0.34%).

Which major investors are selling ObsEva stock?

OBSV stock was sold by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank, Marshall Wace LLP, Marshall Wace LLP, and Banque Cantonale Vaudoise.

Which major investors are buying ObsEva stock?

OBSV stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Deutsche Bank AG, Simplex Trading LLC, Jump Financial LLC, Susquehanna International Group LLP, Renaissance Technologies LLC, and Group One Trading L.P..

How do I buy shares of ObsEva?

Shares of OBSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ObsEva's stock price today?

One share of OBSV stock can currently be purchased for approximately $3.15.

How much money does ObsEva make?

ObsEva has a market capitalization of $181.29 million and generates $20,000.00 in revenue each year. The company earns $-82,970,000.00 in net income (profit) each year or ($1.67) on an earnings per share basis.

How many employees does ObsEva have?

ObsEva employs 45 workers across the globe.

What is ObsEva's official website?

The official website for ObsEva is www.obseva.com.

Where are ObsEva's headquarters?

ObsEva is headquartered at Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228.

How can I contact ObsEva?

ObsEva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company can be reached via phone at (122) 552-3840 or via email at [email protected].